Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors
Translational study published in Nature Communications (2021)
Abstract
Despite their limitations, unfractionated heparin (UFH) and bivalirudin remain standard-of-care parenteral anticoagulants for percutaneous coronary intervention (PCI). We discovered novel direct thrombin inhibitors (DTIs) from tick salivary transcriptomes and optimised their pharmacologic activity. The most potent, ultravariegin, inhibits thrombin with a Ki of 4.0 pM, 445-fold better than bivalirudin. Unexpectedly, despite their greater antithrombotic effect, variegin/ultravariegin demonstrated less bleeding, achieving a 3-to-7-fold wider therapeutic index in rodent thrombosis and bleeding models. When used in combination with aspirin and ticagrelor in a porcine model, variegin/ultravariegin reduced stent thrombosis compared with antiplatelet therapy alone but achieved a 5-to-7-fold lower bleeding time than UFH/bivalirudin. Moreover, two antibodies screened from a naïve human antibody library effectively reversed the anticoagulant activity of ultravariegin, demonstrating proof-of-principle for antidote reversal. Variegin and ultravariegin are promising translational candidates for next-generation DTIs that may reduce peri-PCI bleeding in the presence of antiplatelet therapy.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Ultravariegin, a direct thrombin inhibitor discovered from tick salivary transcriptomes, inhibited thrombin with a Ki of 4.0 pM, 445-fold better than bivalirudin, and together with variegin showed a 3-to-7-fold wider therapeutic index in rodent models; two human antibodies reversed its anticoagulant activity.
Context
This study describes the discovery and optimization of novel direct thrombin inhibitors (variegin and ultravariegin) derived from tick salivary transcriptomes, not from leeches. Ultravariegin inhibits thrombin with a Ki of 4.0 pM (445-fold better than bivalirudin) and demonstrated a 3-to-7-fold wider therapeutic index in rodent thrombosis and bleeding models, with reduced stent thrombosis and shorter bleeding times in a porcine model using aspirin and ticagrelor; two human antibodies reversed its activity as proof-of-principle antidotes. While no leeches are involved, this work pertains to hematophagous-animal-derived anticoagulants, a domain overlapping with leech-derived therapeutics. The study involves no leeches or leech-derived compounds, and all data are preclinical (rodent and porcine models).
Citation
Reference (Vancouver style)
Koh CY, Shih N, Yip CYC, Li AWL, Chen W, Amran FS, et al. Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors. Nat Commun. 2021;12(1):6912. doi:10.1038/s41467-021-27275-8. PMID: 34824278
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026